Evaluation of ⁶⁴Cu-ATSM for an internal radiotherapy agent: ⁶⁴Cu-ATSM treatment reduces CD133⁺ highly tumorigenic cells and metastatic ability of tumors

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.